[go: up one dir, main page]

AR103492A1 - ANTI-LAG3 ANTIBODIES AND ANTIGEN UNION FRAGMENTS - Google Patents

ANTI-LAG3 ANTIBODIES AND ANTIGEN UNION FRAGMENTS

Info

Publication number
AR103492A1
AR103492A1 ARP150102652A ARP150102652A AR103492A1 AR 103492 A1 AR103492 A1 AR 103492A1 AR P150102652 A ARP150102652 A AR P150102652A AR P150102652 A ARP150102652 A AR P150102652A AR 103492 A1 AR103492 A1 AR 103492A1
Authority
AR
Argentina
Prior art keywords
fragment
antibody
antigen
association
amino acid
Prior art date
Application number
ARP150102652A
Other languages
Spanish (es)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR103492A1 publication Critical patent/AR103492A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Reivindicación 1: Un anticuerpo o fragmento de unión a antígeno del mismo que se une específicamente a LAG3 humano que comprende: (a) la CDR1, CDR2, y CDR3 de un dominio VL de una cadena de inmunoglobulina que comprende la secuencia de aminoácidos expuesta en SEC ID Nº 7, 17, 27, 37, 57, 59, 61, 63, 65, 101, 126, 130, 132, 136, 138, 208, 210, 224, 226, 228, 230, 232, 241, 257, 259, 261, 263, 351, 369, 371, 373, 375, 401, 403, 405, 426, 427, 450 - 453 ó 459 - 461 ; y/o; (b) la CDR1, CDR2, y CDR3 de un dominio VH de una cadena de inmunoglobulina que comprende la secuencia de aminoácidos expuesta en SEC ID Nº 2, 12, 22, 32, 45, 47, 49, 51, 53, 55, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 103, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 128, 134, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 212, 214, 216, 218, 220, 222, 234, 235, 237, 239, 243, 245, 247, 249, 251, 253, 255, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 347, 349, 353, 355, 357, 359, 361, 363, 365, 367, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 406 - 419, 434 - 442, 448, 449, 462, 463 ó 464. Reivindicación 11: Una composición o kit que comprende el anticuerpo o fragmento de cualquiera de las reivindicaciones 1 - 10 en asociación con un agente terapéutico adicional. Reivindicación 12: Un polipéptido que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en 2, 3, 4, 5, 7, 8, 9, 10, 12, 13, 14, 15, 17, 18, 19, 20, 22, 23, 24, 25, 27, 28, 29, 30, 32, 33, 34, 35, 37, 38, 39, 40, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 255, 257, 259, 261, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 347, 349, 351, 353, 355, 357, 359, 361, 363, 365, 367, 369, 371, 373, 375, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 426, 427, 434, 435, 436, 437, 438, 439, 440, 441, 442, 446, 448, 449, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463 y 464; o un fragmento maduro y/o un dominio de inmunoglobulina variable del mismo. Reivindicación 17: Una vacuna que comprende un antígeno y un vehículo farmacéuticamente aceptable en asociación con un anticuerpo o fragmento o composición de cualquiera de las reivindicaciones 1 - 11. Reivindicación 21: Un método de tratamiento de cáncer en un sujeto, que comprende administrar al sujeto una cantidad eficaz del anticuerpo o fragmento de unión a antígeno o composición o vacuna de una cualquiera de las reivindicaciones 1 - 11, 16 y 17 opcionalmente, en asociación con un procedimiento terapéutico. Reivindicación 27: Un método para detectar en una muestra la presencia de un péptido LAG3 o un fragmento del mismo, que comprende poner en contacto la muestra con un anticuerpo o fragmento de unión a antígeno de una cualquiera de las reivindicaciones 1 - 10 y detectar la presencia de un complejo entre el anticuerpo o fragmento y el péptido; en el que la detección del complejo indica la presencia del péptido LAG3.Claim 1: An antibody or antigen-binding fragment thereof that specifically binds to human LAG3 comprising: (a) the CDR1, CDR2, and CDR3 of a VL domain of an immunoglobulin chain comprising the amino acid sequence set forth in SEQ ID NO. 7, 17, 27, 37, 57, 59, 61, 63, 65, 101, 126, 130, 132, 136, 138, 208, 210, 224, 226, 228, 230, 232, 241, 257 , 259, 261, 263, 351, 369, 371, 373, 375, 401, 403, 405, 426, 427, 450-453 or 459-461; I; (b) the CDR1, CDR2, and CDR3 of an VH domain of an immunoglobulin chain comprising the amino acid sequence set forth in SEQ ID NO: 2, 12, 22, 32, 45, 47, 49, 51, 53, 55, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 103, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 128, 134, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 212, 214, 216, 218, 220, 222, 234, 235, 237, 239, 243, 245, 247, 249, 251, 253, 255, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 347, 349, 353, 355, 357, 359, 361, 363, 365, 367, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 406-419, 434-442, 448, 449, 462, 463 or 464. Claim 11: A composition or kit comprising the anticue rpo or fragment of any of claims 1-10 in association with an additional therapeutic agent. Claim 12: A polypeptide comprising an amino acid sequence selected from the group consisting of 2, 3, 4, 5, 7, 8, 9, 10, 12, 13, 14, 15, 17, 18, 19, 20, 22 , 23, 24, 25, 27, 28, 29, 30, 32, 33, 34, 35, 37, 38, 39, 40, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63 , 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 106, 108, 110, 112, 114 , 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164 , 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214 , 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 255, 257, 259, 261, 263 , 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287, 289, 291, 293, 295, 297, 299, 301, 303, 305, 307, 309, 311, 313 , 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 347, 349, 351, 353, 355, 357, 359 , 361, 363, 365, 367, 369, 371, 373, 375, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 406, 407 , 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 426, 427, 434, 435, 436, 437, 438, 439, 440, 441, 442, 446, 448 , 449, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463 and 464; or a mature fragment and / or a variable immunoglobulin domain thereof. Claim 17: A vaccine comprising an antigen and a pharmaceutically acceptable carrier in association with an antibody or fragment or composition of any of claims 1-11. Claim 21: A method of treating cancer in a subject, comprising administering to the subject an effective amount of the antibody or antigen-binding fragment or composition or vaccine of any one of claims 1-11, 16 and 17 optionally, in association with a therapeutic procedure. Claim 27: A method of detecting in a sample the presence of a LAG3 peptide or a fragment thereof, comprising contacting the sample with an antibody or antigen binding fragment of any one of claims 1-10 and detecting the presence of a complex between the antibody or fragment and the peptide; in which the detection of the complex indicates the presence of the LAG3 peptide.

ARP150102652A 2014-08-19 2015-08-18 ANTI-LAG3 ANTIBODIES AND ANTIGEN UNION FRAGMENTS AR103492A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462039081P 2014-08-19 2014-08-19

Publications (1)

Publication Number Publication Date
AR103492A1 true AR103492A1 (en) 2017-05-17

Family

ID=58951264

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102652A AR103492A1 (en) 2014-08-19 2015-08-18 ANTI-LAG3 ANTIBODIES AND ANTIGEN UNION FRAGMENTS

Country Status (2)

Country Link
AR (1) AR103492A1 (en)
EC (1) ECSP17016757A (en)

Also Published As

Publication number Publication date
ECSP17016757A (en) 2017-03-31

Similar Documents

Publication Publication Date Title
AR111630A1 (en) ANTI-SIRPa ANTIBODIES
AR106991A1 (en) NEUTRALIZING ANTIBODIES OF THE HUMAN IMMUNODEFICIENCY VIRUS
AR106184A1 (en) PD-1 BINDING PROTEINS AND THEIR METHODS OF USE
PE20120475A1 (en) SPECIFIC ANTIBODIES FOR DKK-1
AR102732A1 (en) T-CELL ACTIVATING ANTIGEN BINDING MOLECULES OF ANTIGEN
AR096617A1 (en) ANTI-TWEAKR ANTIBODIES AND THEIR USES
BR112018075737A2 (en) antibody, composition, isolated cell, and methods for treating cancer or infection in a patient and for detecting pd-11 expression in a sample.
FI3332006T3 (en) Novel anti-pd-l1 antibodies
PE20191208A1 (en) ANTI-CD73 ANTIBODIES AND USES OF THEM
AR095980A1 (en) SPECIFIC BIESPECTIFIC ANTIBODIES FOR FAP (FIBROBLASTIC ACTIVATION PROTEIN) AND DR5 (DEATH RECEIVER 5), SPECIFIC ANTIBODIES FOR DR5 AND METHODS OF USE
AR101848A1 (en) ANTI-B7-H4 AND IMMUNOCATE PLAYERS
MX2020009037A (en) ANTIBODIES TO B7-H4 AND METHODS OF USING THEM.
PE20141908A1 (en) CD47 ANTIBODIES AND METHODS OF USE THEM
AR109882A1 (en) ANTI-TL1A NEUTRALIZING MONOCLONAL ANTIBODIES
EA201891435A1 (en) HUMANIZED MONOCLONAL ANTIBODIES, MONOCLONAL ANTIBODIES MOUSE OR CHEMERIC MONOCLONAL ANTIBODIES AGAINST CD47
AR103442A1 (en) ANTIBODIES AND RECEIVERS OF SPECIFIC CHEMICAL ANTIGENS OF ROR1
PE20171180A1 (en) ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE
BR112017003194A2 (en) antibody or antigen-binding fragment thereof, composition, polypeptide, polynucleotide, vector, host cell, vaccine, vessel or injection device, and methods for antagonizing lag3 in a human patient in need thereof for treating cancer in an individual for administering the antigen-binding antibody, fragment, composition, polypeptide, vaccine, vector or polynucleotide to an individual for producing an antibody or antigen-binding fragment thereof or polypeptide; and to detect the presence of a lag3 peptide or fragment thereof in a sample.
AR103868A1 (en) ANTI-CD47 ANTIBODIES AS THERAPEUTIC AGENTS
PE20221580A1 (en) THERAPEUTIC ANTIBODIES AND THEIR USES
PE20071055A1 (en) ANTI MN ANTIBODIES
AR084210A1 (en) PROTEINS OF UNION TO TNF-a
PE20131209A1 (en) ANTI-FAP ANTIBODIES
PE20142322A1 (en) ANTI-GCC ANTIBODY MOLECULES AND USE OF THEM TO TEST SUSCEPTIBILITY TO GCC TARGETED THERAPY
CL2018003608A1 (en) Isolated antibody or antigen binding fragment thereof that specifically binds interleukin-25 hjumana (il-2525); pharmaceutical composition comprising it; use of said pharmaceutical composition to treat a disease or disorder associated with the activity or expression of il-25. (divisional application 201700703)

Legal Events

Date Code Title Description
FC Refusal